Additionally, KLF5 expression is reduced in prostate cancer, leading to the inhibition of angiogenesis [40], whereas in breast cancer, KLF5 promotes angiogenesis by binding to the promoters of tumor necrosis factor (TNF)α-induced protein 2 (TNFAIP2) [41]. Here, TNFAIP2 is linked to breast cancer.